title: [Drug Therapy for Shock-Resistant Ventricular Fibrillation: Comparison of Nifekalant and Amiodarone].
abstract: Early direct current (DC) shock is the most important therapy for ventricular fibrillation. Following the increased availability of automated external defibrillators (AED), the survival rate of cardiopulmonary arrest patients with ventricular fibrillation has improved. Although patients with shock-resistant ventricular fibrillation require additional antiarrhythmic drug therapy, the optimal protocol has not been established. Nifekalant is a pure potassium channel blocker with a pyrimidinedione structure. Nifekalant was approved in Japan for the treatment of life-threatening ventricular tachyarrhythmias in 1999, and is widely used as a class III antiarrhythmic intravenous drug. Intravenous amiodarone was approved in Japan in 2007, and exhibits various effects on ion channels, receptors, sympathetic activity, and thyroid function. Nifekalant and amiodarone also exhibit many pharmacological and pharmacodynamic differences. As nifekalant has no negative inotropic effect and a rapid action and clearance with a short half-life, it has some advantages over amiodarone for use in cardiopulmonary resuscitation. Indeed, data from clinical and animal studies suggest that nifekalant is superior to amiodarone for resuscitation of cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. A 300-mg bolus intravenous injection of amiodarone is considered an overdose for resuscitation of shock-resistant ventricular fibrillation. Further clinical studies are required to evaluate the effects of nifekalant compared with amiodarone, and to determine the optimal dose of amiodaone, for resuscitation of shock-resistant ventricular fibrillation.
authors.affiliation: Intensive Care Medicine, University Hospital of Occupational and Environmental Health, Japan.
authors.forename: Nobuya
authors.initials: N
authors.lastname: Harayama
authors.forename: Shun-Ichi
authors.initials: S
authors.lastname: Nihei
authors.forename: Keiji
authors.initials: K
authors.lastname: Nagata
authors.forename: Keiji
authors.initials: K
authors.lastname: Aibara
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kamochi
authors.forename: Takeyoshi
authors.initials: T
authors.lastname: Sata
mesh_terms: D000638:Amiodarone / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D047548:Defibrillators; D006801:Humans; D007275:Injections, Intravenous; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D014693:Ventricular Fibrillation / Q000188:drug therapy*
chemical_list: D018927:Anti-Asthmatic Agents; D026902:Potassium Channel Blockers; D011744:Pyrimidinones; C076259:nifekalant; D000638:Amiodarone